Recent events
Recent events tied to this brand in public sources.
Back to profile2 entries
2020
Gilead completes acquisition of Immunomedics
Gilead completed its acquisition of Immunomedics for approximately $21 billion. Immunomedics became a wholly owned subsidiary of Gilead, and its common stock was to cease trading on Nasdaq.
2020
Immunomedics announces CEO appointment
Immunomedics announced that its board appointed Harout Semerjian as president and chief executive officer, effective April 16, 2020.